China flags 'high-pressure' antitrust enforcement stance for pharmaceuticals
Pharmaceutical companies in China face sustained antitrust scrutiny, with regulators signaling a “high-pressure” enforcement stance as Beijing rolls out new guidelines to strengthen oversight of drug pricing. Enforcement will target key categories...To view the full article, register now.
Already a subscriber? Click here to view full article